Morphological response to therapy of breast carcinoma;Therapieinduzierte tumorregression beim mammakarzinom

Pathologe

Volumn 25, Issue 6, 2004, Pages 455-460

  Langer F ^a   Luck H J ^a   Kreipe, H H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Breast cancer; Chemotherapy; Grading; Histology; Regression

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CELL COUNT; CELL VACUOLE; CHEMOSENSITIVITY; CYTOPLASM; FIBROSIS; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MORPHOLOGY; ONCOGENE NEU; PROGNOSIS; PROTEIN EXPRESSION; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 11144346122     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-004-0713-6     Document Type: Article

References (30)

1. Aktepe F, Kapucuoglu N, Pak I (1996) The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology 29:63-67
2. Amat S, Penault-Llorca F, Cure H et al. (2002) Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 20:791-796
3. Anderson BO (2003) Pathologic response to preoperative systemic therapy: the new biological paradigm for predicting outcome and planning therapy. Ann Surg Oncol 10:713-715
4. Bonadonna G, Valagussa P, Brambilla C et al. (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100
5. Brain E, Garrino C, Misset JL et al. (1997) Long-term prognostic and predictive factors in 107 stage II/ III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer 75:1360-1367
6. Buzdar AU, Singletary SE, Theriault RL et al. (1999) Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417
7. Chevallier B, Roche H, Olivier JP et al. (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16:223-228
8. Chollet P, Charrier S, Brain E et al. (1997) Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33:862-866
9. Chollet P, Amat S, Cure H et al. (2002) Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86:1041-1046
10. El-Didi MH, Moneer MM, Khaled HM, Makarem S (2000) Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. Surg Today 30:249-254
11. Feldman LD, Hortobagyi GN, Buzdar AU et al. (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578-2581
12. Fisher B, Bryant J, Wolmark N et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
13. Fisher ER, Wang J, Bryant J et al. (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95:681-695
14. Kennedy S, Merino MJ, Swain SM, Lippman ME (1990) The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. Hum Pathol 21:192-198
15. Kuerer HM, Newman LA, Smith TL et al. (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469
16. Machiavelli MR, Romero AO, Perez JE et al. (1998) Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4:125-131
17. Minckwitz von G, Raab G, Schutte M et al. (2001) Präoperative Chemotherapie operabler primärer Mammakarzinome mit einer dosisddichten Kombination von Adriamycin und Docetaxel (Adoc) - Die Erfahrungen der GEPARDO-GABG-Studiengruppe. Zentralbl Gynakol 123:497-504
18. Moll UM, Chumas J (1997) Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer. Pathol Res Pract 193:187-196
19. Moore GH, Schiller JE, Moore GK (2004) Radiation-induced histopathologic changes of the breast: the effects of time. Am J Surg Pathol 28:47-53
20. Moreno A, Escobedo A, Benito E et al. (2002) Pathologic changes related to CMF primary chemotherapy in breast cancer. Pathological evaluation of response predicts clinical outcome. Breast Cancer Res Treat 75:119-125
21. Newman LA, Pernick NL, Adsay V et al. (2003) Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 10:734-739
22. Olson JA Jr, Fey J, Winawer J et al. (2000) Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer. J Am Coll Surg 191:593-599
23. Penault-Llorca F, Cayre A, Bouchet Mishellany F et al. (2003) Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22:1319-1325
24. Pinder SE, Murray S, Ellis IO et al. (1998) The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 83:1529-1539
25. Rajan R, Poniecka A, Smith TL et al. (2004) Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 100:1365-1373
26. Rasbridge SA, Gillett CE, Seymour AM et al. (1994) The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70:335-341
27. Sharkey FE, Addington SL, Fowler LJ et al. (1996) Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 9:893-900
28. Sinn HP, Schmid H, Junkermann H et al. (1994) Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie. Geburtshilfe Frauenheilkd 54:552-558
29. Vincent-Salomon A, Jouve M, Genin P et al. (2002) HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94:2169-2173
30. Wang J, Buchholz TA, Middleton LP et al. (2002) Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 94:3107-3114